



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

(11) International Publication Number:

WO **00/3**5481

A61K 39/295, A61P 31/12

A2

(43) International Publication Date:

22 June 2000 (22.06.00)

(21) International Application Number:

PCT/CA99/01194

(22) International Filing Date:

16 December 1999 (16.12.99)

(30) Priority Data:

09/213,770

17 December 1998 (17.12.98)

(71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue, Toronto, Ontario M2R 374 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CATES, Accorge, A. [CA/CA]; 37 Remberton Road, Richmond Hill, Ontario b4C 3T5 (CA). SAMBHARA, Suryaprakash [CA/CA]; 50 Harness Circle, Markham, Ontario L3S 1Y1 (CA). BURT, David [CA/CA]; 47 Dakin Drive, Ajax, Ontario L1T 2S2 (CA). KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA).

(74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: MULTIVALENT IMMUNOGENIC COMPOSITION CONTAINING RSV SUBUNIT COMPOSITION AND INFLUENZA VIRUS PREPARATION

(57) Abstract

Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition, when formulated as a vaccine for in vivo administration, do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.